TomoTherapy Inc

TomoTherapy — Merger or Acquisition (March 2011)

22 slides from TomoTherapy's merger presentation, Mar 8, 2011

  1. Slide 1: Creating the Premier Radiation Oncology Company

    Creating the Premier Radiation Oncology Company

  2. Slide 2: Forward-looking Statement Safe Harbor Statement

    Forward-looking Statement Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry and the transaction between Accuray and TomoTherapy. Except for the historical inform

  3. Slide 3: Agenda

    Agenda Welcome Tom RathjenDeal Summary Euan ThomsonCorporate and Product Overview Accuray Overview (Euan Thomson)TomoTherapy Overview (Fred Robertson)Financial Profile Derek BertocciExecutive Summary Euan Thomson Q&A All

  4. Slide 4: Strategic Rationale

    Strategic Rationale Complementary patient populations, treated by the same medical specialtySignificant increase in global presenceFinancial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company

  5. Slide 5: Deal Summary

    Deal Summary

  6. Slide 6: Deal Terms

    Deal Terms TomoTherapy shareholders to receive $4.80 per share* in cash and stock $3.15 in cash0.1648 shares of Accuray stock ($1.65)Expected to be accretive to Accuray's EPS in its fiscal year beginning July 1, 2012Approved by both companies' Board of DirectorsAnticipated to close in Q2 or early Q3

  7. Slide 7: Corporate and Product Overview

    Corporate and Product Overview

  8. Slide 8: Accuray Incorporated

    Accuray Incorporated Accuray Incorporated 200+ systems installed 100,000+ patients treated 75+ issued patents *as of December 31, 2010

  9. Slide 9: Accuray Record of Achievement

    Accuray Record of Achievement Consistent record of technology innovationRegular upgrades support premium service programsNew CyberKnife(r) platforms support stronger pricingProven ability to drive market acceptanceNew productsNew clinical capabilitiesProfitabilityProduct gross profit margin (>60% in

  10. Slide 10: TomoTherapy Incorporated

    TomoTherapy Incorporated Data provided by TomoTherapy Headquarters Madison, WI International Office Brussels NASDAQ Ticker: TOMO Employees 636* Revenue (FY2010) $195M Guidance (FY2011) $215-$235M Product Backlog $133M* 350 systems** 110,000+ patients treated 130+ issued patents **Shipped and/or inst

  11. Slide 11: TomoTherapy Corporate and Product Strategy

    TomoTherapy Corporate and Product Strategy r TOMOTHERAPY(r) PLATFORMDaily CT guidance capabilitiesUnique helical delivery of IMRT Highly conformal dose distributions for simple and complex target volumesEnhanced platform versatility with TomoDirect(tm), TomoHD(tm) and TomoMobile(tm) TOMOTHERAPY INCO

  12. Slide 12: Financial Profile

    Financial Profile

  13. Slide 13: Keys to Financial Success of Acquisition

    Keys to Financial Success of Acquisition Product Revenue: Maintain / GrowBest in class IMRT technologyProfitable product revenueContinue growth in orders and revenue seen in CY 2010Service: Turn From Loss to ProfitImprove product reliabilityReduce cost of serviceCost Synergies: Reduce Operating Expe

  14. Slide 14: Product Revenue

    Product Revenue Customer RelationshipsSignificantly larger sales forceEnhanced and more frequent customer contactsGreater Global PresenceDirect service opportunitiesDirect sales opportunities in select countriesLarger product portfolioMore opportunities for customer contactR&D (future product initia

  15. Slide 15: Service Actions to Turn Profitable

    Service Actions to Turn Profitable Fast Track Program (quarter ended December 31, 2010)Upgrade specific systems with high service costsTomoTherapy Plan: Design, Serviceability, TrainingDesign changes to enhance reliability and serviceabilityRevise procedures and training in manufacturing and service

  16. Slide 16: Cost Synergies

    Cost Synergies Examples Reduced G&A ExpensesPublic Company "overhead"e.g. Audit fees, SEC filings Corporate management duplicationMarketing ExpenseTrade show attendanceProfessional membership feesUsers' eventsExpected Gross Operating Expense Synergies Approximately $25M per year by year two

  17. Slide 17: Summary Corporate Metrics

    Summary Corporate Metrics Metric Accuray TomoTherapy Revenue (CY2010) $206.1M $195.4M Net Income (CY2010) $6.8M ($29.9M) Expected Gross Operational Synergies Approx. $25M per year Approx. $25M per year Product Backlog (Dec. 31, 2010) $170M* $133M** Installed Base 222 (12/31/10) 350*** (2/17/11) *Bas

  18. Slide 18: Executive Summary

    Executive Summary

  19. Slide 19: Increased Global Presence

    Increased Global Presence Worldwide Install Base (CHART) (CHART) 572 Systems Installed** Worldwide Accuray TomoTherapy Americas EIMEA Japan APAC (CHART) Accuray Post Transaction 222 Systems Installed* 350 Systems Installed** *Installed as of December 31, 2010**Shipped and/or installed as of February

  20. Slide 20: Strategic Rationale

    Strategic Rationale Complementary patient populations, treated by the same medical specialtySignificant increase in global presenceFinancial benefits anticipated from operating efficiencies and G&A synergies Combining two best-in-class technologies to create the premier radiation oncology company

  21. Slide 21: Q&A

    Q&A

  22. Slide 22: Creating the Premier Radiation Oncology Company

    Creating the Premier Radiation Oncology Company 3 3 4 5 6 **** Accuray Acquisition of TomoTherapy Key Messages 1 • Combining two best-in-class technologies to create the premier radiation oncology company Safe Harbor Statement The foregoing may contain certain forward-looking statements that involve

TomoTherapy — Merger or Acquisition (March 2011) on 6ix